《新股消息》中通快遞第二上市最多集資121億元 入場費13,535元
中通快遞(ZTO.US)上周通過香港第二上市的上市聆訊,據其於美國申報文件中披露,公司計劃發售4,500萬股股票,當中5%作公開發售,發售價不超過268元,較周二收盤價31.37美元溢價約10%,最多集資120.6億元。每手50股,入場費13,535.03元,預計於9月29日掛牌。高盛為獨家保薦人。
中通快遞將以同股不同權架構上市,將為會是繼小米(01810.HK)、美團點評(03690.HK)、阿里巴巴(09988.HK)及京東(09618.HK)後,第五家以同股不同權新例上市的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.